glp 1 agonist diabetes GLP-1 Receptor Agonists as Treatments for Type 2 Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Incretin agonist clinical trials most frequently reveal nausea as an adverse effect
Emerging preclinical evidence suggests GLP-1 may influence neuronal survival, synaptic plasticity, and neuroinflammationprocesses that are disrupted in neurodegenerative conditions
So if you know you're interested in GLP-1 drugs, you can specifically look for a plan that covers them
Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH, et al
However, the consistency, magnitude, and biological plausibility of the ASCO GI 2026 signal strongly justify future randomized prevention trials
